<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534933</url>
  </required_header>
  <id_info>
    <org_study_id>1014/2020</org_study_id>
    <nct_id>NCT04534933</nct_id>
  </id_info>
  <brief_title>Flow Controlled Ventilation in Thoracic Surgery</brief_title>
  <official_title>Flow Controlled Ventilation Versus Pressure Controlled Ventilation in Thoracic Surgery With One Lung Ventilation - a Prospective, Randomized Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates effects of individualized (by compliance guided pressure settings)&#xD;
      flow-controlled ventilation compared to best clinical practice pressure-controlled&#xD;
      ventilation in thoracic surgery requiring one lung ventilation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Flow-controlled ventilation (FCV) is a novel ventilation method with promising first results&#xD;
      in porcine studies as well as clinical trials. A more efficient and maybe lung protective&#xD;
      ventilation strategy would be crucial in the challenging situation of one lung ventilation&#xD;
      during thoracic surgery, when the whole gas exchange has to be provided by just one half of&#xD;
      the lungs. It could not only improve respiratory values, but also decrease the incidence of&#xD;
      postoperative pulmonary complications, which is a major cause of death after thoracic&#xD;
      surgery.&#xD;
&#xD;
      Thus, individualized FCV, based on compliance guided pressure settings, will be compared to&#xD;
      best clinical practice pressure-controlled ventilation in thoracic surgery requiring one lung&#xD;
      ventilation in a randomized controlled trial. Based on a previous preclinical trial improved&#xD;
      oxygenation will be expected and thus arterial partial pressure of oxygen (pO2) is the main&#xD;
      primary outcome parameter of this study. Furthermore, improved recruitment of lung tissue due&#xD;
      to controlled expiratory flow in FCV will be anticipated without the need of recruitment&#xD;
      maneuvers, which may cause deleterious effects on lung tissue.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2020</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>controlled, prospective</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Horowitz Index</measure>
    <time_frame>after 30 minutes of one lung ventilation</time_frame>
    <description>arterial partial pressure of oxygen (paO2) / fraction of inspired oxygen (FiO2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pulmonary shunt fraction</measure>
    <time_frame>after 30 minutes of one lung ventilation</time_frame>
    <description>calculation of pulmonary shunt fraction via arterial and central venous blood gas analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Positive-Pressure Respiration, Intrinsic</condition>
  <arm_group>
    <arm_group_label>FCV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artificial ventilation will be performed with individualized flow-controlled ventilation (Evone, Ventinova Medical B.V., Eindhoven, the Netherlands) during thoracic surgery. Individualisation will be established by compliance guided end-expiratory and peak pressure setting during double lung ventilation as well as one lung ventilation, flow setting will be adjusted to secure normocapnia and I:E Ratio set to 1:1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Artificial ventilation will be performed with low tidal volume pressure-controlled ventilation (Primus, Dräger, Lübeck, Germany) during thoracic surgery. Peak pressure will be set to achieve a tidal volume of 7ml/kg predicted body weight at a compliance titrated positive end-expiratory pressure in double lung ventilation and 6ml/kg PBW in one lung ventilation. Respiratory rate will be set to maintain normocapnia and I:E ratio set to 1:1.5 except extension of expiration is necessary in order to avoid air trapping.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evone</intervention_name>
    <description>Airway ventilation device</description>
    <arm_group_label>FCV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Primus</intervention_name>
    <description>Airway ventilation device</description>
    <arm_group_label>PCV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects ≥ 18 years&#xD;
&#xD;
          -  Body weight ≥ 40 kg&#xD;
&#xD;
          -  Size of double lumen tube ≥ 37 CH&#xD;
&#xD;
          -  Elective thoracic surgery requiring OLV&#xD;
&#xD;
          -  ASA I-III&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Female subjects known to be pregnant&#xD;
&#xD;
          -  Known participation in another interventional clinical trial&#xD;
&#xD;
          -  high pulmonary risk (ppo FEV1&lt;20ml/kg in male or ppo FEV1&lt;18ml/kg in female)&#xD;
&#xD;
          -  Empyema evacuation or signs of pulmonary infection&#xD;
&#xD;
          -  High grade CMP (EF&lt;30%)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Martini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Innsbruck, Dept. of Anaesthesiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Spraider, MD</last_name>
    <phone>0043 512 504 80329</phone>
    <email>patrick.spraider@i-med.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judith Martini, MD</last_name>
    <phone>0043 512 504 80478</phone>
    <email>judith.martini@i-med.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Spraider, MD</last_name>
      <phone>0043 512 504 80329</phone>
      <email>patrick.spraider@i-med.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Judith Martini, MD</last_name>
      <phone>0043 512 504 80478</phone>
      <email>judith.martini@i-med.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Judith Martini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Spraider, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Abram, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Schmidt J, Wenzel C, Mahn M, Spassov S, Cristina Schmitz H, Borgmann S, Lin Z, Haberstroh J, Meckel S, Eiden S, Wirth S, Buerkle H, Schumann S. Improved lung recruitment and oxygenation during mandatory ventilation with a new expiratory ventilation assistance device: A controlled interventional trial in healthy pigs. Eur J Anaesthesiol. 2018 Oct;35(10):736-744. doi: 10.1097/EJA.0000000000000819.</citation>
    <PMID>29734208</PMID>
  </reference>
  <reference>
    <citation>Weber J, Schmidt J, Straka L, Wirth S, Schumann S. Flow-controlled ventilation improves gas exchange in lung-healthy patients- a randomized interventional cross-over study. Acta Anaesthesiol Scand. 2020 Apr;64(4):481-488. doi: 10.1111/aas.13526. Epub 2019 Dec 30.</citation>
    <PMID>31828755</PMID>
  </reference>
  <reference>
    <citation>Weber J, Straka L, Borgmann S, Schmidt J, Wirth S, Schumann S. Flow-controlled ventilation (FCV) improves regional ventilation in obese patients - a randomized controlled crossover trial. BMC Anesthesiol. 2020 Jan 28;20(1):24. doi: 10.1186/s12871-020-0944-y.</citation>
    <PMID>31992213</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>flow controlled ventilation</keyword>
  <keyword>pressure controlled ventilation</keyword>
  <keyword>thoracic surgery</keyword>
  <keyword>one lung ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Positive-Pressure Respiration, Intrinsic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

